Anita van de Munckhof, Erik Lindgren, Timothy J Kleinig, Thalia S Field, Charlotte Cordonnier, Katarzyna Krzywicka, Sven Poli, Mayte Sánchez van Kammen, Afshin Borhani-Haghighi, Robin Lemmens, Adrian Scutelnic, Alfonso Ciccone, Thomas Gattringer, Matthias Wittstock, Vanessa Dizonno, Annemie Devroye, Ahmed Elkady, Albrecht Günther, Alvaro Cervera, Annerose Mengel, Beng Lim Alvin Chew, Brian Buck, Carla Zanferrari, Carlos Garcia-Esperon, Christian Jacobi, Cristina Soriano, Dominik Michalski, Zohreh Zamani, Dylan Blacquiere, Elias Johansson, Elisa Cuadrado-Godia, Fabrice Vuillier, Felix J Bode, François Caparros, Frank Maier, Georgios Tsivgoulis, Hans D Katzberg, Jiangang Duan, Jim Burrow, Johann Pelz, Joshua Mbroh, Joyce Oen, Judith Schouten, Julian Zimmermann, Karl Ng, Katia Garambois, Marco Petruzzellis, Mariana Carvalho Dias, Masoud Ghiasian, Michele Romoli, Miguel Miranda, Miriam Wronski, Mona Skjelland, Mostafa Almasi-Dooghaee, Pauline Cuisenier, Seán Murphy, Serge Timsit, Shelagh B Coutts, Silvia Schönenberger, Simon Nagel, Sini Hiltunen, Sophie Chatterton, Thomas Cox, Thorsten Bartsch, Vahid Shaygannejad, Zahra Mirzaasgari, Saskia Middeldorp, Marcel M Levi, Johanna A Kremer Hovinga, Katarina Jood, Turgut Tatlisumak, Jukka Putaala, Mirjam R Heldner, Marcel Arnold, Diana Aguiar de Sousa, José M Ferro, Jonathan M Coutinho
BACKGROUND: Cerebral venous thrombosis (CVT) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe condition, with high in-hospital mortality rates. Here, we report clinical outcomes of patients with CVT-VITT after SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination who survived initial hospitalization. METHODS: We used data from an international registry of patients who developed CVT within 28 days of SARS-CoV-2 vaccination, collected until February 10, 2022...
September 9, 2022: Stroke; a Journal of Cerebral Circulation